Market Indices
Sector Heatmap
IMVT — Immunovant, Inc. Common Stock
NasdaqImmunovant, Inc. Common Stock
- O
- 33.99
- H
- 33.99
- L
- 32.95
- V
- 1.1M
IMVT — Latest News & Headlines
20 StoriesImmunovant (IMVT) Just Gave Investors Something To Think About - Yahoo Finance
Immunovant (IMVT) Just Gave Investors Something To Think About Yahoo Finance
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) - prnewswire.com
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) prnewswire.com
Roivant reports top-line data from IMVT-1402 CLE trial - Clinical Trials Arena
Roivant reports top-line data from IMVT-1402 CLE trial Clinical Trials Arena
Understanding Momentum Shifts in (IMVT) - Stock Traders Daily
Understanding Momentum Shifts in (IMVT) Stock Traders Daily
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down - The Globe and Mail
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down The Globe and Mail
Is Trial Failure Altering The Investment Case For Immunovant Stock (IMVT)? - Simply Wall Street
Is Trial Failure Altering The Investment Case For Immunovant Stock (IMVT)? Simply Wall Street
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) Seeking Alpha
Immunovant stock rating maintained at Buy by H.C. Wainwright - Investing.com
Immunovant stock rating maintained at Buy by H.C. Wainwright Investing.com
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows - Yahoo Finance
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows Yahoo Finance
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. Stock Titan
Is Immunovant (IMVT) Undervalued On Its CLE Trial Setback? - Simply Wall Street
Is Immunovant (IMVT) Undervalued On Its CLE Trial Setback? Simply Wall Street
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case - Yahoo Finance
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case Yahoo Finance
How Investors May Respond To Immunovant (IMVT) Skin Lupus Drug Halt - Simply Wall Street
How Investors May Respond To Immunovant (IMVT) Skin Lupus Drug Halt Simply Wall Street
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss Yahoo Finance
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next - Yahoo Finance
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next Yahoo Finance
Is Immunovant (IMVT) Undervalued As CLE Trial Results Raise Fresh Questions? - Simply Wall Street
Is Immunovant (IMVT) Undervalued As CLE Trial Results Raise Fresh Questions? Simply Wall Street
IMVT Mar 2027 20.000 put (IMVT270319P00020000) Stock Price, News, Quote & History - Yahoo! Finance Canada
IMVT Mar 2027 20.000 put (IMVT270319P00020000) Stock Price, News, Quote & History Yahoo! Finance Canada
IMVT Oct 2026 36.000 call (IMVT261016C00036000) Interactive Stock Chart - Yahoo! Finance Canada
IMVT Oct 2026 36.000 call (IMVT261016C00036000) Interactive Stock Chart Yahoo! Finance Canada
Why is Immunovant stock sliding today? - Investing.com
Why is Immunovant stock sliding today? Investing.com
Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding - Kalkine Media
Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding Kalkine Media